STAGE IV PROSTATE CANCER AJCC V8

This study tests whether combining vidutolimod and nivolumab can help the immune system attack and destroy prostate cancer cells that have spread to other parts of the body. The trial includes men with metastatic castration-resistant prostate cancer who have already tried other t…

This study tests a combination of three drugs (abiraterone, prednisone, and apalutamide) in 60 men with prostate cancer that has spread but hasn't yet been treated with hormone therapy. The goal is to see how long men can stay on treatment and how well it controls the cancer. Par…

This early-phase trial tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in people with advanced prostate, bladder, or kidney cancer that has spread. The goal is to find the safest dose and see if the combination can help control the cancer. About 65 adults wi…

This study tests the safety and effectiveness of combining the immunotherapy drug avelumab with other treatments (utomilumab, anti-OX40 antibody, and radiation) in people with advanced cancers that have spread. About 173 adults whose cancer has not responded to standard therapies…

This study tests whether adding rucaparib to standard enzalutamide helps men with advanced prostate cancer that has spread and stopped responding to hormone therapy. About 61 men will receive either the combination or enzalutamide alone. The goal is to see if the combo delays can…

This study looks at whether men with metastatic prostate cancer that has responded extremely well to hormone therapy can safely take a break from treatment. The goal is to see if pausing therapy allows their testosterone levels to return to normal, potentially improving quality o…

This early-phase trial studies whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate. About 15 participants with cancer that has spread will receive the co…

This study tests a two-step treatment for men with an aggressive form of prostate cancer that has spread. First, patients get chemotherapy plus an immunotherapy drug. Then, they take a maintenance pill (niraparib) either alone or with more immunotherapy. The goal is to see if thi…

This early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…

This study tests whether combining two drugs—golimumab (which reduces inflammation) and apalutamide (which blocks male hormones)—can shrink or slow advanced prostate cancer that no longer responds to standard hormone therapy. Eight men with metastatic castration-resistant prostat…

This study is testing whether a shorter, more intense course of radiation has fewer side effects for men whose prostate cancer has returned and spread to a few lymph nodes. It compares two radiation methods: proton beam therapy and standard IMRT. The main goal is to see which app…

This study is testing if adding an experimental drug called berzosertib to a standard chemotherapy (carboplatin) works better for treating advanced prostate cancer that has spread and stopped responding to hormone therapy. It compares this new combination to the standard treatmen…